Specialty pharmaceutical company BioPharmX has announced that it will immediately initiate a Phase 2a clinical study under its U.S. FDA Investigational New Drug (IND) application for BPX-01, a hydrophilic topical formulation of minocycline. The study will assess the drug's effectiveness in reducing the number of acne-causing bacteria in patients at four weeks as well as evaluate its safety and tolerability.
The company’s preclinical studies have found that BPX-01, a unique gel formulation of minocycline, can deliver the antibiotic to the layer of skin where the acneic condition develops while minimizing systemic exposure. The hydrophilic formulation is designed to distribute evenly without occluding or irritating the skin.
“We are excited to begin our IND study of BPX-01,” said Kin F. Chan, PhD, executive vice president of research and development at BioPharmX. “Our nonclinical research has been well received by the dermatology community.”
For more information, visit www.biopharmx.com.
